Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06444802
Other study ID # TTU 08.922
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date September 1, 2024
Est. completion date June 30, 2026

Study information

Verified date May 2024
Source University of Hamburg-Eppendorf
Contact Flaminia Olearo, MD
Phone 00491738815647
Email f.olearo@uke.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Study Rationale: Previous in vitro and retrospective in vivo studies suggest that optimal linezolid concentrations (between 2 and 7 mg/L) achieve clinical efficacy and microbiological eradication while minimizing side effects like thrombocytopenia and the emergence of resistance. No prospective or randomized clinical trial has confirmed these findings, and there is no consensus on how to adjust linezolid dosing to achieve optimal drug concentrations. Objectives: The primary objective is to determine if model-informed precision dosing optimizes linezolid dosing to achieve therapeutic trough concentrations compared to a standard dose. Secondary objectives include assessing the PK/PD profile, investigating the prevalence of linezolid resistance among gram-positive bacteria, assessing microbiological resolution of infection, and evaluating the safety and tolerability of linezolid. Methodology: This study is an open, monocentric pilot randomized controlled trial with two arms: standard dose therapy versus dose adjustment based on model-informed precision dosing using therapeutic drug monitoring and PK/PD targets developed in TMDx software. Sample Size: 28 patients, 14 in each group. Assumptions are based on only 25% of patients in intensive care achieving the optimal therapeutic range with standard dosing, compared to an expected 80% achieving this with model-informed precision dosing. Selection Criteria: Adult patients (18+ years) already starting linezolid treatment for gram-positive infections, expected to require treatment beyond the next calendar day. Exclusions include imminent death, expected or confirmed pregnancy, expected linezolid treatment of less than 4 days or more than 4 weeks. Outcomes: The primary endpoint is defined as the difference in the proportion of patients in the intervention and in the control groups who maintained a trough linezolid concentration of 2 to 7 mg/L on Day 7 and Day 13.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 28
Est. completion date June 30, 2026
Est. primary completion date February 28, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. = 18 years of age 2. Linezolid treatment is indicated or has been started due to pneumonia, skin or soft tissue infection; the patient has received no more than 2 infusions of 600 mg linezolid each 3. with written informed consent of the patient or 4. with written informed consent of his/her legal representative or 5. after using the option of inclusion via spouse according to § 1358 BGB or 6. after application of the independent consultant procedure 7. Patients of childbearing age: negative pregnancy test Exclusion Criteria: 1. Patients receiving antibiotics active against Gram-positive bacteria at the same time of linezolid 2. Infection other than pneumonia, skin or soft tissue infection, especially tuberculosis, endocarditis and osteomyelitis 3. Death is deemed imminent and inevitable 4. Pregnancy 5. Lactation/breastfeeding

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Linezolid
Linezolid dosing will be adapted according to a model informed precision dosing (TDMx)

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University of Hamburg-Eppendorf

Outcome

Type Measure Description Time frame Safety issue
Primary Through concentration in the target The primary endpoint is defined as the likehood in achieving a trough linezolid concentration of 2 to 8 mg/L on Day 7 Day 7 of linezolid treatment
Secondary Pharmacokinetic: Percentage of the dosing interval while drug concentration remains above the MIC (f%T > MIC) Day 7 and day 13 of linezolid treatment
Secondary Thrombocytopenia Median variation of platelets count after the start up to end of linezolid treatment From the start of linezolid treatment and up to 14 days
Secondary lactic acidosis and peripheral neuropathy Frequency of lactic acidosis and peripheral neuropathy From the start of linezolid treatment and up to 14 days
Secondary Microbiology Time to microbiologic eradication is calculated as the interval between the first isolation of a Gram-positive pathogen causing the infection and the first negative culture from the same type of biological material From the start of linezolid treatment and up to 14 days
Secondary Microbiology Time to development of resistance to linezolid in Gram-positive bacteria is calculated as the interval in days between the first isolation of a specific bacteria species sensitive to linezolid and the first isolation of the same species showing resistance, in any type of biological material. From the start of linezolid treatment and up to 14 days
Secondary Microbiology Rate of Relapse of gram-positive infection (growth of the same gram-positive organism in the blood culture or in another primarily site infected up to EOF). At the end of treatment up to the end of 30 day follow-up
See also
  Status Clinical Trial Phase
Completed NCT01412801 - Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings Phase 2
Terminated NCT00108433 - Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections Phase 3
Completed NCT00501150 - Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Infections N/A
Terminated NCT00529282 - A Study of Ceftobiprole in Patients With Fever and Neutropenia. Phase 3
Completed NCT00079976 - Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA) Phase 3
Terminated NCT00835783 - Validation Study of Combined Positron Emission Tomography/Computer Tomography to Diagnose Infection and Inflammation N/A
Completed NCT00081744 - Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects Phase 3
Completed NCT03747497 - Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection Phase 2
Active, not recruiting NCT04911270 - Clinical Decision Support Tool for Vancomycin Dosing in Children N/A
Completed NCT02750761 - A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013) Phase 1
Completed NCT00406198 - Impact of Continuous Venovenous Haemofiltration on Organ Failure During the Early Phase of Severe Sepsis Phase 4
Completed NCT03560440 - Evaluation of the Dosing Regimen of Vancomycin in Pediatric Patients
Completed NCT00147511 - Time To Efficacy and Onset Of Action Of Linezolid Phase 4
Terminated NCT00240747 - Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients Phase 3
Not yet recruiting NCT04917380 - The Clinical Character,Risk and Prognosis of Post-neurosurgical Intracranial Infection With Different Pathogens.
Completed NCT00736554 - What is the Prevalence of Methicillin-Resistant Staphylococcus Aureus in Skin and Soft Tissue Infections Presenting to the Emergency Departments of a Canadian Academic Health Care Center? N/A
Completed NCT03361163 - Controlled Human Infection for Vaccination Against Streptococcus Pyogenes Phase 1
Completed NCT00167960 - Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit Phase 4
Completed NCT00874367 - Early-Onset Sepsis Surveillance Study N/A
Completed NCT00167999 - Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units Phase 4